Latest news with #Filspari
Business Insider
2 days ago
- Business
- Business Insider
Travere Therapeutics price target raised to $34 from $32 at Citi
Citi raised the firm's price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere. Citi upped the company's estimates to reflect continued demand growth for Filspari in immunoglobulin A nephropathy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
07-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 16, Leerink Partners analyst Joseph Schwartz reiterated the firm's bullish stance on Travere Therapeutics, Inc. (NASDAQ:TVTX), assigning it a Buy rating and a $42 price target. The analyst supported the positive rating with Travere Therapeutics, Inc.'s (NASDAQ:TVTX) positive trajectory, supported by its product Filspari, which attained complete approval for the treatment of IgA nephropathy (IgAN) in 2023. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. When considered in conjunction with the updated treatment guidelines, this approval has resulted in a notable growth in Filspari's market presence. Although competition is anticipated to rise in the IgAN market, the firm anticipates Filspari to hold a competitive market edge due to its full approval status, as other treatments only have accelerated approval. Schwartz also reasoned that Travere Therapeutics, Inc. (NASDAQ:TVTX) is looking into expansion opportunities in focal segmental glomerulosclerosis (FSGS), and a supplemental New Drug Application is under review by the FDA. While such processes have inherent regulatory risks, the analyst expressed optimism about Travere Therapeutics, Inc.'s (NASDAQ:TVTX) prospects because of its strategic positioning and management's confidence. Guggenheim analyst Vamil Divan also reiterated a Buy rating on Travere Therapeutics, Inc.'s (NASDAQ:TVTX) on July 2 with a price target of $47.00. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company that identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), reduces proteinuria in individuals with primary IgAN at risk of rapid disease progression. The company's commercial products, Thiola and Thiola EC, treat cystinuria, a rare genetic cystine transport disorder. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Health
- Yahoo
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis' Fabhalta and Venrafia provide physicians more options than ever before. EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA Nephropathy (IgAN) patients. Data from Spherix Global Insights' comprehensive Patient Chart Dynamix™ services—spanning over 2,300 patient charts across the US, EU5, Japan, and China—demonstrate the magnitude of this shift, highlighting differences in treatment patterns, product adoption, and future intent across markets. As standard treatment practice increasingly incorporates SGLT2 inhibitors—initially reserved for diabetes and then diabetic kidney disease—nephrologists are initiating these agents earlier in the treatment algorithm, citing emerging data supporting their protective effects in CKD, including IgAN. Adoption has grown substantially year-over-year in all surveyed markets. While regional differences exist, the early use of SGLT2 inhibitors, in combination with RAASi, is now widely accepted as foundational care for non-dialysis IgAN patients. Overlaying this supportive care are newly launched agents designed specifically for IgAN. Calliditas' Tarpeyo® (budesonide) and Travere's Filspari® (sparsentan) have quickly gained traction in the US, with prescribing steadily moving upstream in the treatment paradigm. Indeed, nearly one in five US IgAN patients are currently managed with Tarpeyo, and Filspari's use has nearly doubled in the past year alone. Across Europe, Kinpeygo—Tarpeyo's EU label—has seen notable growth, especially in Germany and the UK. Filspari's limited availability at the time of fielding across many regions somewhat constrained its uptake, though future use intentions are high as access expands. In China, Nefecon (budesonide) has rapidly secured a foothold, with many patients already initiated on therapy. Despite different access landscapes, nephrologists are aligned on one key goal: reducing proteinuria to below 0.5g/day. Yet, many patients remain above this threshold despite therapy, underscoring the need for additional, more effective options. Enter Novartis, with Fabhalta® (iptacopan), recently approved in the US and garnering early interest for use in later lines of therapy. Vanrafia®, also from Novartis, has just received its first approval and is poised to further expand the treatment armamentarium. Together, these products—alongside pipeline agents targeting the complement system, APRIL/BAFF pathways, and other novel MOAs—represent a new chapter in IgAN care focused on underlying disease pathophysiology. Importantly, Spherix's data highlight regional nuances in how nephrologists view and sequence these therapies. In Japan, tonsillectomy remains a widely accepted option and is often paired with systemic corticosteroids. In contrast, physicians in the US and China are increasingly moving away from broad immunosuppression in favor of targeted mechanisms with improved safety profiles. While there is general agreement on first-line strategies, subsequent lines of therapy are in flux, shaped by clinical experience, product availability, and evolving guideline recommendations. Physicians continue to prioritize clinical data demonstrating both proteinuria reduction and eGFR preservation when evaluating new options, though safety warnings remain a barrier to adoption for some. Even so, enthusiasm for therapies with novel mechanisms continues to grow, particularly in markets where patients remain difficult to manage despite standard therapies. With over five years of continuous tracking, Spherix Global Insights has established the most robust and consistent global dataset on IgAN, offering the industry's most comprehensive view of how real-world treatment decisions have evolved and how emerging therapies are being integrated into clinical practice. By continuing to track real-world patient management trends and comparing data across markets, Spherix delivers actionable insights that support strategic decision-making for stakeholders across the nephrology landscape. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Spherix Global Insights Contacts Tucker Hurtado, Nephrology Franchise Head NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Tucker Hurtado, Nephrology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-04-2025
- Health
- Associated Press
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving therapeutic landscape. As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating diagnosis, treatment decisions, and the daily realities of living with this chronic kidney condition. Fielded in early 2025 and developed in collaboration with the American Kidney Fund (AKF), the study reflects the voices of 127 patients diagnosed with IgAN. While many report satisfaction with newer branded therapies, substantial gaps persist in patient education, confidence, and affordability. The emotional burden of an IgAN diagnosis remains significant, with most respondents describing initial feelings of fear, confusion, or anxiety. A clear need emerged for better disease education – particularly around treatment expectations, progression, and financial resources. More than one-third of patients rely on support groups or charitable foundations for financial assistance, underscoring the role pharmaceutical companies can play in reducing barriers through accessible, patient-friendly resources. The research places special emphasis on patients currently treated with Tarpeyo, Filspari, and Fabhalta, all of which are associated with symptom relief and improved quality of life. However, challenges persist. Although many patients begin treatment feeling informed, issues related to cost, insurance coverage, and long-term affordability often complicate therapy initiation and adherence. These findings highlight opportunities for manufacturers to enhance onboarding and support through both provider-facing tools and direct-to-patient engagement strategies. The study also integrates insights from Spherix's latest Patient Chart Dynamix™: IgAN (US) study to provide complementary perspectives from nephrologists, offering a comprehensive view of how patient and physician perceptions align, and differ, when it comes to disease severity, treatment satisfaction, and care coordination. For commercial, medical, and access teams preparing to launch or expand within the IgAN space, Patient Dynamix™: IgAN (US) offers a critical resource for shaping brand strategy, refining support services, and ultimately improving patient outcomes. By leveraging these patient-level insights, pharmaceutical organizations can more effectively tailor messaging, reduce drop-off rates, and enhance their position as true partners in IgAN care. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar. AKF Contacts NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
Yahoo
04-04-2025
- Business
- Yahoo
Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed. A group of independent trial monitors on Friday recommended dosing continue in a trio of studies testing Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, Elevidys, after a brief halt. Dosing in the trials was paused earlier this week at the request of the European Medicines Agency, which wanted researchers to conduct an analysis into the recent death of a Duchenne patient treated with Elevidys. On Thursday, they met and concluded Elevidys' 'risk-benefit profile remains favorable' and dosing should resume without any changes to the study protocols, Sarepta said in a statement. Sarepta and Roche, which owns European rights to Elevidys, will share the findings with regulators within a week, after which the EMA will evaluate the findings. The three trials affected include one called Envision that's meant to confirm Elevidys' benefits in Duchenne patients who can no longer walk. — Ben Fidler Novartis on Thursday won accelerated approval of a kidney disease drug it acquired in a $3.2 billion buyout two years ago. Called Vanrafia, the drug was cleared by the Food and Drug Administration for use treating IgA nephropathy, a chronic condition that can lead to kidney failure as well as an increasingly competitive area of pharmaceutical research. Novartis aims to grab market share from Travere Therapeutics' Filspari. One advantage it may have commercially, according to some Wall Street analysts, is that patients on Vanrafia won't need to be periodically checked for liver problems. At about $163,000 per year, Vanrafia is priced at a slight premium to Filspari, which has a list price of just over $151,000. — Ben Fidler Allakos has agreed to be acquired by Concentra Biosciences, a firm controlled by Tang Capital Partners, for $0.33 per share in cash, the company said Wednesday. The deal comes after two strategic resets and a pair of major restructurings for Allakos, a developer of immune disease drugs, in the last two years. It's also the latest bid for a distressed biotech by Concentra, which since 2023 has acquired Theseus Pharmaceuticals and Jounce Therapeutics and amassed stakes in other struggling drugmakers with the intent of buying and liquidating them. — Ben Fidler People in Germany living with hemophilia B now have access to a gene therapy for their condition after maker CSL Behring and a national association of health insurance funds in that country reached an agreement on a reimbursement price. The therapy, which CSL sells as Hemgenix, was conditionally authorized in the European Union in 2023. CSL has already secured access decisions in Denmark, Switzerland, Spain, Austria and the U.K, but said the agreement in Germany is the first time Hemgenix is being made available under a national, success-based reimbursement model. Last summer, two people in France became the first to be commercially treated with Hemgenix in Europe. — Ned Pagliarulo A late-stage study testing a high dose of Roche's multiple sclerosis drug Ocrevus failed to show a benefit over the the currently approved dose, the company disclosed Tuesday. Roche ran the trial to test whether a dose two or three times higher, depending on a patient's weight, could further slow disability progression in people with the relapsing form of the disease. Instead, the data confirmed that Ocrevus is 'optimally dosed,' said Roche Chief Medical Officer Levi Garraway. Roche plans to present full data from the study at an upcoming meeting. The company recently launched a subcutaneous form of the blockbuster drug. — Ned Pagliarulo
